【ChiCTR2000034163】Instructions of daily care in overweight and obese knee osteoarthritis participants
ChiCTR2000034163
尚未开始
/
/
/
2020-06-26
/
/
膝骨关节炎
Instructions of daily care in overweight and obese knee osteoarthritis participants
Feasibility and acceptability of instructions of daily care in overweight and obese knee osteoarthritis participants
54000
To assess the effectiveness and acceptability of instructions of daily care (IDC) on pain, mobility and body mass index among knee osteoarthritis (OA) participants who are overweight or obese.
随机平行对照
其它
Randomization will be done by a computer generated number. After randomization each group will be called separately for their interventions.
Open Label
None
/
20
/
2020-04-15
2020-08-14
/
Overweight or obese knee osteoarthritis participants with grade 2 or 3 (based on Kellgren and Lawrence radiographic scale) Both males and females, Age between 45-60 years, Residing in the urban community of Lahore.；
请登录查看Rheumatoid arthritis; Orthopaedic problem; Spinal deformities or Any previous injections of the knee.；
请登录查看Medical Superintendent, Dr Farid Ahmad Chaudhary
54000
Medical Superintendent, Dr Farid Ahmad Chaudhary的其他临床试验
- The effects of strength training in knee osteoarthritis patients
- Instructions of daily care in overweight and obese knee osteoarthritis participants
- Effectiveness of lower limb rehabilitation protocol using mobile health (LLRP-mHealth) on quality of life, functional strength and functional capacity among knee osteoarthritis patients who are overweight and obese.
巴基斯坦拉合尔木尔坦路木尔坦崇基旁遮普雇员社会保障机构心脏病学研究生院的其他临床试验
- The effects of strength training in knee osteoarthritis patients
- Instructions of daily care in overweight and obese knee osteoarthritis participants
- Effectiveness of lower limb rehabilitation protocol using mobile health (LLRP-mHealth) on quality of life, functional strength and functional capacity among knee osteoarthritis patients who are overweight and obese.
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04